A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens

被引:0
|
作者
Khandelia, Vikash [1 ]
Nama, Umashankar [1 ]
Mahavar, Ashok [1 ]
Rathore, Anjali [1 ]
机构
[1] Govt Med Coll & Hosp, Dept Nephrol, Kota, Rajasthan, India
关键词
Acquired immunodeficiency syndrome; Antiretroviral therapy; Chronic kidney disease; Nephrotoxicity; ANTIRETROVIRAL THERAPY; RENAL DYSFUNCTION; IMPAIRMENT; PREVALENCE;
D O I
10.7860/JCDR/2022/50272.16425
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Exposure to Tenofovir often leads to the development of some irreversible high risk for kidney disease events. In Human Immunodeficiency Virus (HIV) patients, the prolonged treatment with tenofovir use frequently causes mildto-moderate nephrotoxicity. Hence, there is a need to further investigate the efficacy and the adverse effects associated with tenofovir use to combat the decreased morbidity and mortality associated with the declined kidney function. Aim: To investigate the risk of kidney disease associated with tenofovir use. Materials and Methods: A retrospective study was conducted at the tertiary care centre in northern India, from August 2009 to January 2017 and analysed during January to May 2021. The patients with HIV infection who were administered Tenofovir, Lamivudine and Efavirenz (TLE) and Zidovudine, Lamivudine and Nevirapine (ZLN) were included.The patients were divided into two group based on the TLE and ZLN regimen they received. These patients were on a regular follow-up for six months. The data was assessed on the basis of serum creatinine and estimated Glomerular Filtration Rate ( eGFR) (using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), body weight and Cluster of Differentiation (CD4) count. Results: Out of 703 patients, 364 patients were administered with TLE, while 339 patients received ZLN. In both the groups, the number of patients were between the age 21-40 years was significantly higher, followed by patients between the age 4160 years. The mean weight and CD4 count of the patients in both the groups significantly increased with the progression of time (p<0.001). The creatinine levels at baseline and at 24 months were comparable in both the groups, p>0.05. The mean eGFR level was significantly lowered in TLE group (112.2 mL/ min/ 1.73 m(2)) compared to ZLN group (123.5 mL/ min/1.73m(2)) at 24-months follow-up (p<0.001). Conclusion: Overall results demonstrate that increasing exposure to tenofovir was associated with a higher incidence of CKD. The serum creatinine levels were comparable between the TLE and ZLN group.
引用
收藏
页数:3
相关论文
共 50 条
  • [21] Infectious disease events in people with HIV receiving kidney transplantation-analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
    Schreiber, P. W.
    Kouyos, R. D.
    Bernasconi, E.
    Boggian, K.
    Braun, D. L.
    Calmy, A.
    Cavassini, M.
    van Delden, C.
    Furrer, H.
    Garzoni, C.
    Hirsch, H. H.
    Hirzel, C.
    Manuel, O.
    Schmid, P.
    Stoeckle, M.
    Mueller, N. J.
    Guenthard, H. F.
    Kusejko, K.
    HIV MEDICINE, 2023, 24 : 256 - 259
  • [22] Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine
    Chen, Xinhui
    Castillo-Mancilla, Jose R.
    Seifert, Sharon M.
    McAllister, Kevin B.
    Zheng, Jia-Hua
    Bushman, Lane R.
    MaWhinney, Samantha
    Anderson, Peter L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) : 5387 - 5392
  • [23] Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens
    Zachor, Hadas
    Machekano, Rhoderick
    Estrella, Michelle M.
    Veldkamp, Peter J.
    Zeier, Michele D.
    Uthman, Olalekan A.
    Taljaard, Jantjie J.
    Moosa, Mohammed R.
    Nachega, Jean B.
    AIDS, 2016, 30 (08) : 1221 - 1228
  • [24] Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
    Giacomelli, Andrea
    Oreni, Letizia
    Franzetti, Marco
    Di Cristo, Valentina
    Vergani, Barbara
    Morosi, Manuela
    Colella, Elisa
    Galli, Massimo
    Rusconi, Stefano
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 206 - 206
  • [25] Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
    Rosenblatt, Lisa
    Farr, Amanda M.
    Nkhoma, Ella T.
    Nelson, James K.
    Ritchings, Corey
    Johnston, Stephen S.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [26] Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
    Lisa Rosenblatt
    Amanda M. Farr
    Ella T. Nkhoma
    James K. Nelson
    Corey Ritchings
    Stephen S. Johnston
    BMC Infectious Diseases, 16
  • [27] Prevalence and risk factors of measles seronegativity in a cohort of HIV-positive subjects: a retrospective study
    Dauby, N.
    Martin, C.
    Hainaut, M.
    Grammens, T.
    Van den Wijngaert, S.
    Delforge, M.
    De Wit, S.
    HIV MEDICINE, 2018, 19 (06) : 426 - 429
  • [28] Health Care Costs in a Cohort of HIV-Infected US Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine
    Nelson, Richard E.
    Ma, Junjie
    Crook, Jacob
    Knippenberg, Kristin
    Nyman, Heather
    Paul, Damemarie
    Esker, Stephen
    LaFleur, Joanne
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (10): : 1052 - 1066
  • [29] Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study
    Antoniou, T
    Raboud, JM
    Chirhin, S
    Yoong, D
    Govan, V
    Gough, K
    Rachlis, A
    Loutfy, MR
    HIV MEDICINE, 2005, 6 (04) : 284 - 290
  • [30] Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study
    Alemu, Ayinalem
    Yesuf, Aman
    Zerihun, Betselot
    Getu, Melak
    Worku, Teshager
    Bitew, Zebenay Workneh
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 95 : 59 - 66